ADPT Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of -56.92% compared to Adaptive Biotechnologies's net margin of 24.92%. Adaptive Biotechnologies's return on equity of -62.62% beat Biomarin Pharmaceutical's return on equity of 9.62%.

Adaptive Biotechnologies has a consensus price target of $11.14, signalling upside risk potential of 24.78%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $95.91 which suggests that it could grow by 66.65%. Given that Biomarin Pharmaceutical has higher upside potential than Adaptive Biotechnologies, analysts believe Biomarin Pharmaceutical is more attractive than Adaptive Biotechnologies.

Adaptive Biotechnologies has a beta of 1.755, which suggesting that the stock is 75.472% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.157%.

Adaptive Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Adaptive Biotechnologies quarterly revenues are $52.4M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.1M. Adaptive Biotechnologies's net income of -$29.9M is lower than Biomarin Pharmaceutical's net income of $185.7M. Notably, Adaptive Biotechnologies's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 21.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies is 6.97x versus 3.86x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -56.92% compared to Adaptive Biotechnologies's net margin of -49.65%. Adaptive Biotechnologies's return on equity of -62.62% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Adaptive Biotechnologies has a consensus price target of $11.14, signalling upside risk potential of 24.78%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.2%. Given that NovaBay Pharmaceuticals has higher upside potential than Adaptive Biotechnologies, analysts believe NovaBay Pharmaceuticals is more attractive than Adaptive Biotechnologies.

Adaptive Biotechnologies has a beta of 1.755, which suggesting that the stock is 75.472% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Adaptive Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Adaptive Biotechnologies quarterly revenues are $52.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Adaptive Biotechnologies's net income of -$29.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Adaptive Biotechnologies's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies is 6.97x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -56.92% compared to Adaptive Biotechnologies's net margin of --. Adaptive Biotechnologies's return on equity of -62.62% beat Oragenics's return on equity of --.

Adaptive Biotechnologies has a consensus price target of $11.14, signalling upside risk potential of 24.78%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that Oragenics has higher upside potential than Adaptive Biotechnologies, analysts believe Oragenics is more attractive than Adaptive Biotechnologies.

Adaptive Biotechnologies has a beta of 1.755, which suggesting that the stock is 75.472% more volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Adaptive Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Adaptive Biotechnologies quarterly revenues are $52.4M, which are larger than Oragenics quarterly revenues of --. Adaptive Biotechnologies's net income of -$29.9M is lower than Oragenics's net income of -$2.2M. Notably, Adaptive Biotechnologies's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies is 6.97x versus 1.84x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -56.92% compared to Adaptive Biotechnologies's net margin of --. Adaptive Biotechnologies's return on equity of -62.62% beat Theriva Biologics's return on equity of --.

Adaptive Biotechnologies has a consensus price target of $11.14, signalling upside risk potential of 24.78%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1438.46%. Given that Theriva Biologics has higher upside potential than Adaptive Biotechnologies, analysts believe Theriva Biologics is more attractive than Adaptive Biotechnologies.

Adaptive Biotechnologies has a beta of 1.755, which suggesting that the stock is 75.472% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Adaptive Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Adaptive Biotechnologies quarterly revenues are $52.4M, which are larger than Theriva Biologics quarterly revenues of --. Adaptive Biotechnologies's net income of -$29.9M is lower than Theriva Biologics's net income of -$4.3M. Notably, Adaptive Biotechnologies's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies is 6.97x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.